Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine plus Romiplostim N01 for Transfusion-Dependent Non-Severe Aplastic Anemia
ChiCTR2500109038Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine and romiplostim in aplastic anemia, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 6-month overall response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
cyclosporineromiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2500109038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109038.